SYBX
Synlogic, Inc.1.0600
+0.0100+0.95%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
12.40MP/E (TTM)
-Basic EPS (TTM)
-0.26Dividend Yield
0%Recent Filings
8-K
8-K
10-Q
Q2 FY2025 results
Synlogic's Q2 FY2025 results show a sharp pivot from last year's noise, with operating expenses dropping to $0.8M from a $0.4M gain, driven by the February 2024 restructuring that slashed R&D costs 101% y/y to a $0.01M gain after discontinuing the Synpheny-3 trial. Net loss narrowed to $0.5M or $(0.04) per share from $3.1M profit, thanks to a $1.1M gain on warrant liability remeasurement, while YTD net loss of $0.2M reflects $2.0M operating cash burn. Cash holds steady at $17.0M, enough for 12 months amid strategic review for merger or sale. One full-timer steers the ship now. Yet regulatory hurdles in biotech linger as a key risk.
10-Q
Q1 FY2025 results
Synlogic swung to a net profit of $0.3 million in Q1 2025, a stark turnaround from the $25.6 million loss a year earlier, thanks to slashed operating expenses and a $1.0 million gain on remeasuring its warrant liability. Revenue stayed flat at zero, while research and development costs plunged 99% year-over-year to $22,000 amid the post-restructuring wind-down, leaving just one full-time employee. Operating loss narrowed to $0.9 million from $38.8 million, with the net figure boosted by $1.2 million in other income. Cash dipped to $17.3 million, sufficient for at least 12 more months at current lean levels, as the company hunts strategic alternatives like a merger. Free cash flow not disclosed in the 10-Q. Yet regulatory hurdles could stall any revival.
10-K
FY2024 results
Synlogic's FY2024 results reflect a strategic pivot after discontinuing its Phase 3 PKU trial for labafenogene marselecobac in February, halting R&D momentum and slashing expenses by 79% y/y to $9.2M, driven by workforce cuts and program wind-downs. Annual net loss narrowed to $23.4M from $61.3M, with Q4 underscoring the shift: no revenue beyond a minor $8K transfer, yet $16.2M gain from warrant revaluation boosted other income. Cash burn eased to $31.7M, leaving $18.9M in reserves amid active pursuit of mergers or sales—no outlook disclosed, but liquidity supports operations through mid-2025. Yet, clinical trial failures risk derailing any revival.
ENVB
Enveric Biosciences, Inc.
5.24-0.12
IMUX
Immunic, Inc.
0.60-0.01
LXRX
Lexicon Pharmaceuticals, Inc.
1.20-0.03
PTIX
Protagenic Therapeutics, Inc.
1.52-0.07
SABS
SAB Biotherapeutics, Inc.
3.99-0.01
SIGY
Sigyn Therapeutics Inc.
1.71-0.19
TOVX
Theriva Biologics, Inc.
0.21+0.01
XBIO
Xenetic Biosciences, Inc.
2.07-0.27
XBIT
XBiotech Inc.
2.45-0.08
XRTX
XORTX Therapeutics Inc.
0.59-0.01